Lindbrook Capital’s Voyager Therapeutics VYGR Stock Holding History

Lindbrook Capital’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-75	Closed	-$439	–	2916
2024 Q3	$439	Buy	+75	New	+$545	﹤0.01%	2704

Other funds holding VYGR

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lindbrook Capital's VYGR Position: Q4 2024 in Review

Lindbrook Capital sold out of Voyager Therapeutics (VYGR) in Q4 2024, closing a stake of 75 shares — an estimated $439 sold.

Lindbrook Capital first reported a position in VYGR in Q3 2024 and held it in 1 quarter. The position peaked at $439 in Q3 2024. 132 funds tracked by Wall St. Rank hold VYGR as of Q4 2024.

Lindbrook Capital reported no remaining Voyager Therapeutics position as of Q4 2024 after selling out during the quarter.
Lindbrook Capital sold 75 Voyager Therapeutics shares in Q4 2024, an estimated $439.
Lindbrook Capital first reported a position in Voyager Therapeutics in Q3 2024 and held it in 1 quarter.
Lindbrook Capital's Voyager Therapeutics position peaked at $439 in Q3 2024.
132 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2024.

Based on Lindbrook Capital's 13F filing for Q4 2024, filed 6 Feb 2025.